Macquarie’s big data plunge

Macquarie joins the big data research set.

It seems the US arm of Macquarie Equities Research has plenty of clout when it comes to big data.

More to the point, its move to begin coverage of companies in this rather complex area of information technology has been enough to move the share prices of several enterprise big data companies.

Big data is the term used to describe data sets that are so large they are beyond the ability of commonly used software tools to capture, store and manage.

But there are an increasing number of listed companies operating in the big data world, offering platforms and products to manage the growing flow of data across the globe.

While Australia is on the periphery of this growth area, and has no listed big data companies as such, Macquarie has seen fit to tap into the research data stream – and has had an immediate impact.

Shares of enterprise big data companies Qlik Technologies (QLIK), Splunk (SPLK), and Tableau Software\(DATA) all rose after Macquarie analyst Brad Zelnick initiated coverage of them this week, assigning Splunk and Qlik Outperform ratings, and Tableau a Neutral rating.

Zelnick says the market for Splunk, which operates a platform, may be much larger than the core addressable market opportunity of $27 billion.

He notes that Qlik is in the midst of a transition to a new version of its big data product, but believes Tableau’s product is “appealing to the greatest number of business users, given its superior usability vs. competing products” within the category of “data visualisation.” As such, he says estimates for the company’s business are probably “conservative”:

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles